anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Acute upper respiratory tract infections (AURTIs) are prevalent in the general population. However, studies on the association of short-term exposure to air pollution with the risk of hospital visits for AURTIs in adults are limited. This study aimed to explore the short-term exposure to air pollutants among Chinese adults living in Ningbo.
METHODS: Quasi-Poisson time serious regressions with distributed lag non-linear models (DLNM) were applied to explore the association between ambient air pollution and AURTIs cases. Patients ≥ 18 years who visit three hospitals, being representative for urban, urban-rural junction and rural were included in this retrospective study.
RESULTS: In total, 104,441 cases with AURTIs were enrolled in hospital during 2015-2019. The main results showed that particulate matter with an aerodynamic diameter less than 2.5 μm (PM2.5), nitrogen dioxide (NO2) and nitrogen dioxide (SO2), were positively associated to hospital visits for AURTIs, except for nitrogen dioxide (O3), which was not statistically significant. The largest single-lag effect for PM2.5 at lag 8 days (RR = 1.02, 95%CI: 1.08-1.40), for NO2 at lag 13 days (RR = 1.03, 95%CI: 1.00-1.06) and for SO2 at lag 5 days (RR = 1.27, 95%CI: 1.08-1.48), respectively. In the stratified analysis, females, and young adults (18-60 years) were more vulnerable to PM2.5 and SO2 and the effect was greater in rural areas and urban-rural junction.
CONCLUSIONS: Exposure to ambient air pollution was significantly associated with hospital visits for AURTIs. This study provides epidemiological evidence for policymakers to control better air quality and establish an enhanced system of air pollution alerts.
The spread of sexually transmitted infections (STIs) is a significant public health problem. Screening and treating STIs in partners is crucial for interrupting the transmission chain, and it is essential to identify factors that contribute to maintaining it. The objective of this study was to compare the intentions of men and women to adhere to the treatment for STIs diagnosed in their partner as well as the perception of partner adherence. An observational, cross-sectional study was conducted using a self-administered structured questionnaire in Unified Health System (SUS) users who were treated at the Pedro Ernesto University Hospital between August 2023 and January 2024. Overall, 255 questionnaires were analyzed. Among the 42 participants who reported previous STIs, 21 percent maintained risky behavior in their current relationship. Attendance at the consultation in the case of a partner diagnosed with STI was high (90 percent women and 87 percent men); however, unconditional adherence to medication use was 63 percent in women and 55 percent in men, with the duration of medication use and its route of administration highlighted as the possible obstacles. Although no significant differences were observed between men and women, measures to increase adherence to STI treatment are necessary to interrupt STI transmission.
Like other drugs that antagonize dopamine D2 receptors, SECUADO can elevate prolactin levels, and the elevation can persist during chronic administration. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.

In the SECUADO placebo-controlled trial, galactorrhea, amenorrhea, gynecomastia, and impotence were not reported for patients treated with SECUADO or placebo [see Adverse Reactions (6.1)]. 

In sublingual asenapine adult pre-marketing clinical trials, the incidences of adverse events related to abnormal prolactin levels were 0.4% versus 0% for placebo.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of these drugs is considered in a patient with previously-detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.
Provided are modified arenaviruses and populations thereof, wherein the modified arenaviruses include i) an introduced PPXY domain; ii) an increased number of PPXY domains; iii) a substituted amino acid in place of S41 in a viral Z protein that is not a substrate for a serine or tyrosine kinase, or a combination of i)-iii). A PPXY domain can include a phosphomimetic replacement of the Y amino acid. Modified Old World and New World arenaviruses are included. Arenavirus production is provided using cell cultures that contain a kinase inhibitor that inhibits a kinase that can phosphorylate the Y amino acid of the PPXY domain, or by cells that have disrupted kinase gene expression, or by cells that have a disrupted ESCRT system. Also provided are pharmaceutical formulations that contain modified arenaviruses, and methods of using such formulations for stimulating an immune response hat is fully or partially protective against arenavirus infection. Also provided is a method for producing a population of arenaviruses that involves culturing cells that i) are infected with a wild type arenavirus, or ii) comprise one or more expression vectors encoding the arenavirus, wherein the cells are characterized by at least one of: a) comprising kinase inhibitor; or b) a modification such that expression of a kinase capable of phosphorylating a tyrosine in a PPXY domain of the arenavirus is inhibited or eliminated, or c) a disrupted ESCRT pathway.
PURPOSE:To impart the water solubility to allantoin effective for treating wounds, burns, ulcers, dermatopathies, etc. and produce the drug effect thereof sufficiently, by reacting a soidum salt of the allantoin with sodium hydroxymethanesulfonate under weakly alkaline conditions. CONSTITUTION:Allantoin of the formula is dispersed in a weakly alkaline aqueous solution, e.g. aqueous ammonia, and sodium hydroxymethanesulfonate, etc. in an about equimolar amount is added thereto. The resultant reaction mixture is then heated at 100-120 deg.C, and concentrated under reduced pressure. A nontoxic solvent, e.g. ethanol, is then added to the concentrate to collect the resultant precipitate, which is made into any dosage forms, e.g. an aqueous solution, tincture, ointment or paste, according to the purposes.
The invention discloses an antigen fragment and truncation based on ebola virus envelope protein as well as an application. The protein or the truncation of the protein is disclosed by the invention; the protein is shown in SEQ ID No. 3 or protein which is obtained by replacing and/or deleting and/or adding one or more amino acid residues in an amino acid sequence shown in the SEQ ID No. 3 and has the identical function as the protein shown in SEQ ID No. 3. The antigen fragment and the truncation thereof disclosed by the invention can induce relatively strong humoral immune response, has good immunogenicity and can be applied to development of ebola virus vaccines and preparation of neutralizing antibodies.
A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).
The subjects will be given 20mg vonoprazan twice a day, 1000mg amoxicillin three times a day and fucoidan 1000mg twice a day. These three drugs were taken continuously for 14 days.
The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
Thrombocytopenia has occurred primarily with high dose intermittent therapy, but has also been noted after resumption of interrupted treatment. It rarely occurs during well supervised daily therapy. This effect is reversible if the drug is discontinued as soon as purpura occurs. Cerebral hemorrhage and fatalities have been reported when rifampin administration has been continued or resumed after the appearance of purpura.

Rare reports of disseminated intravascular coagulation have been observed.

Leukopenia, hemolytic anemia, and decreased hemoglobin have been observed.

Agranulocytosis has been reported very rarely.
OBJECTIVE: peroral endoscopic myotomy (POEM), a relatively minimally invasive endoscopic procedure, is the first-line treatment for achalasia. The aim of this study was to compare procedure-related parameters and clinical outcomes between bypassing and performing prophylactic electrocoagulation of large submucosal vessels during POEM.
METHODS: one hundred and twelve patients with achalasia who had undergone POEM at our hospital between April 2017 and March 2023 were retrospectively enrolled. Large submucosal vessels were bypassed to avoid injury during submucosal tunneling in the bypass group, whereas large submucosal vessels were prophylactically treated by electrocoagulation in the prophylactic electrocoagulation group. Procedure-related parameters, Eckardt score and complications were compared between the two groups.
RESULTS: the bypass group showed a significant reduction in operative time and amount of intraoperative blood loss than the prophylactic electrocoagulation group (37.11 ± 9.96 min vs 58.80 ± 17.90 min, and 1 [interquartile range: 1-2] ml vs 5 [interquartile range: 3-8] ml; p < 0.001). Eleven (17.5 %) and 44 (89.8 %) patients in the bypass and prophylactic electrocoagulation groups, respectively, required hemostatic forceps (p < 0.001). Furthermore, lower operative and hospitalization costs were recorded in the bypass group than in the prophylactic electrocoagulation group (p < 0.05). No statistically significant difference was found between the two groups in terms of submucosal tunnel length, myotomy length, clinical efficacy, or complications.
CONCLUSIONS: bypassing large submucosal vessels during POEM can reduce the operative duration and intraoperative blood loss, with no difference in clinical outcomes than prophylactic electrocoagulation treatment.
The invention discloses application of macelignan in treating toxoplasmosis. Adding myristyl lignanoid into the culture mediumAnd (3) incubating toxoplasma tachyzoite for 2h, removing the drug culture medium, and continuing to culture for 24h, wherein when the concentration of the myristolignan is higher than 60 mu g/mL, the invasion of the toxoplasma tachyzoite can be completely inhibited, and the dose dependence is presented. The number of cysts, tachyzoites, and average worm size in naematococcus decreased dose-dependently as the concentration of myristolignan increased. Median inhibitory concentration IC of myristolignan on Toxoplasma gondii tachyzoites 50 The value was 31.32. mu.g/mL. Myristica fragrans lignan can inhibit invasion and intracellular replication of Toxoplasma gondii tachyzoite and protect mice acutely infected by Toxoplasma gondii, and ultrastructural observation shows that the inhibitory effect of myristolignan on Toxoplasma gondii is related to mitochondria. The invention shows that the myristyl lignanoid has low cytotoxicity and can safely and effectively treat toxoplasmosis.
Rectal prolapse is characterized by a full-thickness intussusception of the rectal wall and is associated with a spectrum of coexisting anatomic abnormalities. We developed the transabdominal levatorplasty technique for laparoscopic rectopexy, inspired by Altemeier's procedure. In this method, following posterior mesorectum dissection, we expose the levator ani muscle just behind the anorectal junction. Horizontal sutures, using nonabsorbable material, are applied to close levator diastasis associated with rectal prolapse. The aim of the transabdominal levatorplasty is to (i) reinforce the pelvic floor, (ii) narrow the anorectal hiatus, and (iii) reconstruct the anorectal angle. We report a novel transabdominal levatorplasty technique during laparoscopic rectopexy for rectal prolapse. The laparoscopic mesh rectopexy with levatorplasty technique was performed in eight cases: six underwent unilateral Orr-Loygue procedure, one modified Wells procedure, and one unilateral Orr-Loygue procedure combined with sacrocolpopexy for uterine prolapse. The median follow-up period was 178 (33-368) days, with no observed recurrences. Six out of seven patients with fecal incontinence experienced symptomatic improvement. Although the sample size is small and the follow-up period is short, this technique has the potential to reduce the recurrence rate and improve functional outcomes, as with levatorplasty of Altemeier's procedure. We believe that this technique may have the potential to become an option for rectal prolapse surgery.
Hepatic ischemia-reperfusion injury (HIRI) is a major complication reported in various clinical scenarios such as liver transplantation (LTx), hepatectomy, and acute hepatic insult. This condition affects the restoration of hepatic functionalities post-LTx. Contemporary scientific inquiries have highlighted the involvement of intestinal microbiota and their metabolic by-products in the initiation and progression of HIRI. Perturbations in the gut microbiome, instigated by external stressors such as inflammatory processes, ischemic conditions, and reperfusion events, affect the biosynthesis of metabolites such as short-chain fatty acids (SCFAs), bile acids (BAs), and lipopolysaccharides (LPS). SCFAs can exert anti-inflammatory effects, modulate cellular apoptosis, and attenuate oxidative stress, thereby ameliorating hepatic injury. Other studies have shown that the intestinal microbiota confers hepatoprotective effects by modulating the host's immune response and synthesis of cytokines, controlling inflammation, and enhancing liver protection. This review comprehensively describes the mechanisms underlying the association of gut microbiota and its metabolites with hepatic disease and ischemia-reperfusion injury. The findings from recent studies investigating the gut-liver axis are reviewed to identify therapeutic avenues for the prevention and treatment of liver dysfunction and ischemia-reperfusion injury. In-so-doing, novel pathways and perspectives can be exploited to develop therapies for the control of inflammatory hepatic ischemia-reperfusion injury, particularly following liver transplantation or surgical intervention.
All participants in the waitlist control will receive the SBI chatbot 4 weeks later. The intervention has the same content for both intervention and waitlist control groups.
The usual lofexidine tablets starting dosage is three 0.18 mg tablets taken orally 4 times daily during the period of peak withdrawal symptoms (generally the first 5 to 7 days following last use of opioid) with dosing guided by symptoms and side effects. There should be 5 to 6 hours between each dose. The total daily dosage of lofexidine tablets should not exceed 2.88 mg (16 tablets) and no single dose should exceed 0.72 mg (4 tablets). 

Lofexidine tablets treatment may be continued for up to 14 days with dosing guided by symptoms. 

Discontinue lofexidine tablets with a gradual dose reduction over a 2- to 4-day period to mitigate lofexidine tablets withdrawal symptoms (e.g., reducing by 1 tablet per dose every 1 to 2 days). [see Warnings & Precautions(5.5)].The lofexidine tablets dose should be reduced, held, or discontinued for individuals who demonstrate a greater sensitivity to lofexidine tablets side effects [see Adverse Reactions (6.1),Warnings and Precautions(5.1)]. Lower doses may be appropriate as opioid withdrawal symptoms wane. 

Lofexidine tablets can be administered in the presence or absence of food.
PURPOSE:To prepare a coating composition useful for the coating of granules, etc. of drug, exhibiting lowered adhesivity in the coating operation thereby preventing the mutual adhesion of the granules to be coated, and giving a pinhole- free excellent coating film, by adding a specific amount of liquid paraffin, etc. to an aqueous solution of a water-soluble coating base having a specific concentration. CONSTITUTION:The objective composition is prepared by dispersing (A) one or more materials selected from liquid paraffin, silicone oil, vegetable oil, and fatty acid glyceride uniformly in (B) an aqueous solution containing 1.5wt% of a water-soluble drug-coating base (e.g. hydroxypropylmethyl cellulose). The amount of the component (A) is 10-40wt%. The composition is sprayed to the granules to be coated preferably at 48-51 deg.C (exhaust temperature). USE:Coating of tablet, pill, etc. of drug.
The epidemiology and prognosis of radiation-induced chronic pain, especially chronic neuropathic pain (CNP), are the understudied domain among head and neck cancer (HNC) survivors after radiotherapy (RT). This study aimed to estimate the prevalence of such chronic pain, and explore its correlations with mental health, sleep disorders, cognitive function, and quality of life (QOL) within these patients. This research encompassed HNC survivors post RT. The determination of radiation-induced chronic pain and CNP adhered to the guidelines outlined by the International Association for the Study of Pain. Multivariable regression analyses were employed to explore the relationship between pain and anxiety, depression, sleep disturbances, cognitive function, and QOL. A total of 1,071 HNC survivors post RT were included in this study. The prevalence of radiation-induced chronic pain was 67.1%, and the prevalence of RT-associated CNP was 38.3%. Compared with those reporting no pain, patients with radiation-induced chronic pain had a significantly increased risk of anxiety, depression, and sleep disorders (all P < .001). And there was a significantly negative association between chronic pain and QOL across physiological (P < .001), psychological (P < .001), social relationships (P = .001), and environmental (P = .009) domains. Compared with non-CNP, patients with RT-related CNP had a higher risk of anxiety (P = .027) and sleep disorders (P = .013). The significantly negative associations were found between CNP and the physiological (P = .001), psychological (P = .012), and social score (P = .035) in World Health Organisation Quality of Life Assessment-Bref. This study underscores the substantial prevalence of chronic pain, particularly CNP, and its potential impact on the mental health, sleep, and QOL among HNC survivors post RT. PERSPECTIVE: This study highlights the high prevalence of radiation-induced chronic pain and CNP, and their potential impacts on anxiety, depression, sleep, and QOL among the HNC survivors. Clinically, these findings have important implications for improving the care and outcomes of HNC survivors.
Acrivastine was absorbed rapidly from the combination capsule following oral administration and was as bioavailable as a solution of acrivastine. After administration of SEMPREX-D Capsules, maximum plasma acrivastine concentrations were achieved at 1.14 ± 0.23 hour. A mass balance study in 7 healthy volunteers showed that acrivastine is primarily eliminated by the kidneys. Over a 72-hour collection period, about 84% of the administered total radioactivity was recovered in urine and about 13% in feces, for a combined recovery of about 97%. Further, 67% of the administered radioactive dose was recovered in urine as the unchanged drug, 11% as the propionic acid metabolite, and 6% as other unknown metabolites.

Acrivastine exhibits linear kinetics over dosages ranging from 2 to 32 mg t.i.d. The mean ± SD terminal half-life for acrivastine was 1.9 ± 0.3 hours following single oral doses and increased to 3.5 ± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 ± 1.4 hours. Because of the short half-lives of both acrivastine and its metabolites, accumulation in the plasma following multiple dosing is not expected.

The steady-state maximum acrivastine plasma concentration was 227 ± 47 ng/mL. The oral clearance, and apparent volume of distribution were 2.9 ± 0.7 mL/min/kg and 0.46 ± 0.05 L/kg, respectively, following a single oral dose; oral clearance did not change at steady state (2.86 ± 0.75 mL/min/kg). The apparent volume of distribution increased to 0.82 ± 0.6 L/kg to parallel the increase in the elimination half-life of the drug.

Acrivastine binding to human plasma proteins was 50 ± 2.0% and was concentration-independent over the range of 5 to 1000 ng/mL. The main binding protein was serum albumin although the drug was slightly bound to α-1-acid glycoprotein. No displacement interaction was observed between acrivastine and either phenytoin or theophylline. The binding of acrivastine was not affected by the presence of pseudoephedrine.

Pseudoephedrine hydrochloride was also rapidly absorbed from the combination capsule, and the capsule was as bioavailable as a solution of pseudoephedrine. Steady state maximum plasma concentration for pseudoephedrine was 498 ± 129 ng/mL. The terminal half-life, oral clearance and apparent volume of distribution were 6.2 ± 1.8 hours, 5.9 ± 1.7 mL/min/kg, and 3.0 ± 0.4 L/kg, respectively. Elimination of pseudoephedrine is primarily through the renal route as 55 to 75% of an administered dose appears unchanged in the urine. Pseudoephedrine elimination, however, is highly dependent upon urine pH; the plasma half-life decreased to about 4 hours at pH 5 and increased to 13 hours at pH 8.

Pseudoephedrine did not bind to human plasma proteins over the concentration range of 50 to 2000 ng/mL.

Acrivastine and pseudoephedrine do not influence the pharmacokinetics of the other drug when administered concomitantly.
The present invention relates to a Chinese medicinal preparation--Jiazhuangling for treating hyperthyroidism, thyroma, thyroid cyst and endemic goiter. The preparation has obvious effect, short course of treatment, low relapse rate and dismission of the trouble of taking medicines for a long time. 218 cases of patients with various kinds of hyperthyroidism are observed in clinic, and the patients can be cured within three months. The preparation can cure thyroma, thyroid cyst, endemic goiter, etc. within two months. The total effective rate is 98.6%, the cure rate is 90.8%, the ineffective rate is 1.4%, and the relapse rate within five years is only 1.8%.
PURPOSE: Provided is a cosmetic composition including an extract of mung-bean hull which contains a large amount of vitexin or isovitexin exhibiting inhibition effect on melanin-production. The composition has excellent skin whitening effect and stability. CONSTITUTION: The cosmetic composition useful notably in skin whitening contains 0.001 to 20.0% by weight of an extract of mung-bean hull, based on the total weight of the composition. Mung beans(Phaseolus radiatus L.) are soaked in water for 10 to 24hr and peeled. The mung-bean hull is ground, added with 3 to 5 times of a solvent and then extracted at 50 to 90deg.C for 1 to 20hr. The solvent is selected from water, C1-4 anhydrous or hydrous lower alcohol, acetone, ethylacetate, chloroform, 1,3-butylene glycol.